Research coauthored by RTI Health Solutions researchers will be presented at EAHAD 2023.
Patient experience with efanesoctocog alfa: results from the XTEND-1 phase 3 clinical (EAHAD) trial exit interviews in patients with severe haemophilia A. Wilson A, Kragh N, DiBenedetti D, Bystricka L, Pan-Petesch B, Wynn T, Neme D, Willemze A. Poster
@EAHADnews
